163 related articles for article (PubMed ID: 7634548)
1. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism.
Dressler R; Laut J; Lynn RI; Ginsberg N
Clin Nephrol; 1995 May; 43(5):324-31. PubMed ID: 7634548
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Intravenous calcitriol in the treatment of the refractory secondary hyperparathyroidism of terminal chronic kidney failure].
Almirall J; Torregrosa V; Arrizabalaga P; Cases A; Oliva J
Med Clin (Barc); 1994 Mar; 102(9):325-8. PubMed ID: 8164458
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
[TBL] [Abstract][Full Text] [Related]
5. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD.
Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M
Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842
[TBL] [Abstract][Full Text] [Related]
7. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
[TBL] [Abstract][Full Text] [Related]
8. [Low dosage intravenous calcitriol bolus therapy in chronic hemodialysis patients].
Neyer U; Wöss E; Drexel H
Acta Med Austriaca; 1994; 21(5):129-32. PubMed ID: 7709710
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients.
Delmez JA; Kelber J; Norwood KY; Giles KS; Slatopolsky E
Clin Nephrol; 2000 Oct; 54(4):301-8. PubMed ID: 11076106
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.
Fischer ER; Harris DC
Clin Nephrol; 1993 Oct; 40(4):216-20. PubMed ID: 8261678
[TBL] [Abstract][Full Text] [Related]
11. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
12. Improvement of secondary hyperparathyroidism and reduction of the set point of calcium after intravenous calcitriol.
Malberti F; Surian M; Cosci P
Kidney Int Suppl; 1993 Jun; 41():S125-30. PubMed ID: 8320905
[TBL] [Abstract][Full Text] [Related]
13. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
14. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
15. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
[TBL] [Abstract][Full Text] [Related]
17. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
18. [Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis].
Szołkiewicz M; Zdrojewski Z; Sulima-Gillow A; Rutkowski B
Przegl Lek; 1996; 53(5):427-30. PubMed ID: 8754407
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
20. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
